Generic placeholder image

Current HIV Research


ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Research Article

Performance of a Modified In-House HIV-1 Avidity Assay among a Cohort of Newly Diagnosed HIV-1 Infected Individuals and the Effect of ART on the Maturation of HIV-1 Specific Antibodies

Author(s): Diviya Alex, Tennison Inba Raj Williams, Jaiprasath Sachithanandham, Swaminathan Prasannakumar, John Paul Demosthenes, Veena Vadhini Ramalingam, Punitha John Victor, Priscilla Rupali, Gnanadurai John Fletcher and Rajesh Kannangai*

Volume 17, Issue 2, 2019

Page: [134 - 145] Pages: 12

DOI: 10.2174/1570162X17666190712125606

Price: $65


Background: Viral kinetics impact humoral immune response to HIV; antibody avidity testing helps distinguish recent (<6 months) and long-term HIV infection. This study aims to determine the frequency of recent HIV-1 infection among clients attending ICTC (Integrated Counselling and Testing Centre) using a commercial EIA, to correlate it with a modified in-house avidity assay and to study the impact of ART on anti-HIV-1 antibody maturation.

Methods: Commercial LAg Avidity EIA was used to detect antibody avidity among 117 treatment naïve HIV-1 infected individuals. A second-generation HIV ELISA was modified for in-house antibody avidity testing and cutoff was set based on Receiver Operating Characteristic (ROC) analysis. Archived paired samples from 25 HIV-1 infected individuals before ART and after successful ART; samples from 7 individuals responding to ART and during virological failure were also tested by LAg Avidity EIA.

Results: Six individuals (5.1%) were identified as recently infected by a combination of LAg avidity assay and HIV-1 viral load testing. The modified in-house avidity assay demonstrated sensitivity and specificity of 100% and 98.2%, respectively, at AI=0.69 by ROC analysis. Median ODn values of individuals when responding to ART were significantly lower than pre-ART [4.136 (IQR 3.437– 4.827) vs 4.455 (IQR 3.748–5.120), p=0.006] whereas ODn values were higher during virological failure [4.260 (IQR 3.665 – 4.515) vs 2.868 (IQR 2.247 – 3.921), p=0.16].

Conclusion: This modified in-house antibody avidity assay is an inexpensive method to detect recent HIV-1 infection. ART demonstrated significant effect on HIV-1 antibody avidity owing to changes in viral kinetics.

Keywords: Avidity assay, LAg avidity assay, HIV, recent infection, ART, India.

Graphical Abstract
World Health Organization. When and how to use assays for recent infection to estimate HIV incidence at a population level 2011.
Hallett TB. Estimating the HIV incidence rate: recent and future developments. Curr Opin HIV AIDS 2011; 6(2): 102-7.
[] [PMID: 21505383]
Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 2010; 24(18): 2763-71.
[] [PMID: 20975514]
Mastro TD. Determining HIV incidence in populations: moving in the right direction. J Infect Dis 2013; 207(2): 204-6.
[] [PMID: 23129757]
World Health Organization. World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance 2012. 04768_eng.pdf
UNAIDS/WHO. Technical update on HIV incidence assays for surveillance and monitoring purposes 2015.
World Health Organization WHO | HIV drug resistance report. 2017.
Moyo S, LeCuyer T, Wang R, et al. Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence. AIDS Res Hum Retroviruses 2014; 30(1): 29-36.
[] [PMID: 23937344]
Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008; 13(36): 18966.
[PMID: 18775293]
Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol 1995; 141(2): 166-72.
[] [PMID: 7817972]
Smoleń-Dzirba J, Wąsik TJ. Current and future assays for identifying recent HIV infections at the population level. Med Sci Monit 2011; 17(5): RA124-33.
[] [PMID: 21525823]
McDougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006; 22(10): 945-52.
[] [PMID: 17067263]
Kim AA, Hallett T, Stover J, et al. Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One 2011; 6(3): e17535.
[] [PMID: 21408182]
Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002; 18(4): 295-307.
[] [PMID: 11860677]
Suligoi B, Galli C, Massi M, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol 2002; 40(11): 4015-20.
[] [PMID: 12409368]
Barin F, Meyer L, Lancar R, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005; 43(9): 4441-7.
[] [PMID: 16145089]
Suligoi B, Rodella A, Raimondo M, et al. Avidity Index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol 2011; 49(7): 2610-3.
[] [PMID: 21543577]
Parekh BS, McDougal JS. New Approaches For Detecting Recent HIV-1 Infection. AIDS Rev 2001; 3: 183-93.
Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280(1): 42-8.
[] [PMID: 9660362]
Martró E, Suligoi B, González V, et al. Comparison of the avidity index method and the serologic testing algorithm for recent Human Immunodeficiency Virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections. J Clin Microbiol 2005; 43(12): 6197-9.
[] [PMID: 16333129]
Gao Z, Yan H, Feng X, et al. Development of a new limiting-antigen avidity dot immuno-gold filtration assay for HIV-1 incidence. PLoS One 2016; 11(8): e0161183.
[] [PMID: 27513563]
Hauser A, Santos-Hoevener C, Meixenberger K, et al. Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort. PLoS One 2014; 9(6): e98038.
[] [PMID: 24892795]
Thomas HI, Wilson S, O’Toole CM, et al. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin Exp Immunol 1996; 103(2): 185-91.
[] [PMID: 8565298]
Curtis KA, Kennedy MS, Charurat M, et al. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum Retroviruses 2012; 28(2): 188-97.
[] [PMID: 21585287]
Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010; 26(1): 61-71.
[] [PMID: 20063992]
Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003; 32(4): 424-8.
[] [PMID: 12640201]
Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol 2007; 45(2): 415-20.
[] [PMID: 17151211]
Re MC, Schiavone P, Bon I, et al. Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. Int J Infect Dis 2010; 14(11): e1008-12.
[] [PMID: 20869896]
Wendel SK, Mullis CE, Eshleman SH, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One 2013; 8(2): e55525.
[] [PMID: 23437058]
National AIDS Control Organisation, Ministry of Health & Family Welfare, Government of India. National Guidelines for HIV Testing. 2015. Guidelines_for_HIV_Testing_21Apr2016.pdf
Laeyendecker O, Gray RH, Grabowski MK, et al. Validation of the limiting antigen avidity assay to estimate level and trends in HIV incidence in an A/D epidemic in Rakai, Uganda. AIDS Res Hum Retroviruses 2019; 35(4): 364-7.
[] [PMID: 30560723]
Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012; 7(3): e33328.
[] [PMID: 22479384]
Laeyendecker O, Konikoff J, Morrison DE, et al. Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. J Int AIDS Soc 2018; 21(2): 21.
[] [PMID: 29489059]
Konikoff J, Brookmeyer R, Longosz AF, et al. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS One 2013; 8(12): e82772.
[] [PMID: 24386116]
Duong YT, Kassanjee R, Welte A, et al. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One 2015; 10(2): e0114947.
[] [PMID: 25710171]
Kassanjee R, Pilcher CD, Keating SM, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS 2014; 28(16): 2439-49.
[] [PMID: 25144218]
Mani M, Ramalingam VV, Lionel J, et al. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission. Indian J Med Microbiol 2015; 33(2): 225-30.
[] [PMID: 25865972]
Truong HM, Fatch R, Grant RM, et al. Characterization of HIV recent infection among high-risk men at public STI clinics in Mumbai. AIDS Behav 2018; 22(Suppl. 1): 70-5.
[] [PMID: 29453551]
Solomon SS, Celentano DD, Srikrishnan AK, et al. Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. Am J Epidemiol 2010; 172(11): 1259-67.
[] [PMID: 20935070]
Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191(9): 1403-9.
[] [PMID: 15809897]
Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198(5): 687-93.
[] [PMID: 18662132]
Anderson RM, May RM. Epidemiological parameters of HIV transmission. Nature 1988; 333(6173): 514-9.
[] [PMID: 3374601]
Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. Am J Epidemiol 1998; 148(1): 88-96.
[] [PMID: 9663408]
Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39(4): 446-53.
[] [PMID: 16010168]
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20(10): 1447-50.
[] [PMID: 16791020]
Colfax GN, Buchbinder SP, Cornelisse PGA, Vittinghoff E, Mayer K, Celum C. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16(11): 1529-35.
[] [PMID: 12131191]
Moyo S, Kotokwe KP, Mohammed T, et al. Low false recent rate of limiting antigen-avidity assay combined with HIV-1 RNA data in Botswana. AIDS Res Hum Retroviruses 2016; 33(1): 17-8.
[PMID: 27481530]
Keating SM, Hanson D, Lebedeva M, et al. Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation. J Clin Microbiol 2012; 50(12): 3968-76.
[] [PMID: 23035182]
Masciotra S, Dobbs T, Candal D, et al. Antibody avidity-based assay for identifying recent HIV-1 infections Based on Genetic Systems [TM] 1/2 Plus O EIA [#937 17th Conf Retroviruses Opportunistic Infect. San Francisco, CA. 2010.
Kassanjee R, Pilcher CD, Busch MP, et al. Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS 2016; 30(15): 2361-71.
[] [PMID: 27454561]
Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G. Molecular epidemiology of HIV. Indian J Med Res 2005; 121(4): 333-44.
[PMID: 15817947]
Neogi U, Bontell I, Shet A, et al. Molecular epidemiology of HIV-1 subtypes in India: Origin and evolutionary history of the predominant subtype C. PLoS One 2012; 7(6): e39819.
[PMID: 22768132]
Sahni AK, Prasad VVSP, Seth P. Genomic diversity of human immunodeficiency virus type-1 in India. Int J STD AIDS 2002; 13(2): 115-8.
[] [PMID: 11839166]
Gadkari DA, Moore D, Sheppard HW, Kulkarni SS, Mehendale SM, Bollinger RC. Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res 1998; 107: 1-9.
[PMID: 9529774]
Mandal D, Jana S, Panda S, et al. Distribution of HIV-1 subtypes in female sex workers of Calcutta, India. Indian J Med Res 2000; 112: 165-72.
[PMID: 12452124]
Ramalingam S, Kannangai R, Vijayakumar TS, et al. Subtype & cytokine profiles of HIV infected individuals from south India. Indian J Med Res 2005; 121(4): 226-34.
[PMID: 15817940]
Jameel S, Zafrullah M, Ahmad M, Kapoor GS, Sehgal S. A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants. AIDS 1995; 9(7): 685-90.
[] [PMID: 7546411]
Shen C, Craigo J, Ding M, Chen Y, Gupta P. Origin and dynamics of HIV-1 subtype C infection in India. PLoS One 2011; 6(10): e25956.
[] [PMID: 22016790]
Rodriguez MA, Ding M, Ratner D, et al. High replication fitness and transmission efficiency of HIV-1 subtype C from India: Implications for subtype C predominance. Virology 2009; 385(2): 416-24.
[] [PMID: 19157481]
Shepherd SJ, McAllister G, Kean J, et al. Development of an avidity assay for detection of recent HIV infections. J Virol Methods 2015; 217: 42-9.
[] [PMID: 25721468]
Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68(8): 5142-55.
[PMID: 8035514]
Parekh BS, Pau CP, Kennedy MS, Dobbs TL, McDougal JS. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res Hum Retroviruses 2001; 17(2): 137-46.
[] [PMID: 11177393]
Selleri M, Orchi N, Zaniratti MS, et al. Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr 2007; 46(2): 145-50.
[] [PMID: 17589369]
Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193(2): 169-80.
[] [PMID: 11148221]
Smith D, Berrey MM, Robertson M, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182(3): 950-4.
[] [PMID: 10950796]
Adalid-Peralta L, Grangeot-Keros L, Rudent A, et al. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med 2006; 7(8): 514-9.
[] [PMID: 17105510]
Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40(6): 868-73.
[] [PMID: 15736021]
Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42(5): 700-8.
[] [PMID: 16447118]
Le Guillou-Guillemette H, Renier G, Vielle B, et al. Immune restoration under HAART in patients chronically infected with HIV-1: diversity of T, B, and NK immune responses. Viral Immunol 2006; 19(2): 267-76.
[] [PMID: 16817769]
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384(9939): 258-71.
[] [PMID: 24907868]
Hayashida T, Gatanaga H, Tanuma J, Oka S. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 2008; 24(3): 495-8.
[] [PMID: 18327979]
Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179(3): 527-37.
[] [PMID: 9952358]
Binley JM, Trkola A, Ketas T, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182(3): 945-9.
[] [PMID: 10950795]
Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407(6803): 523-6.
[] [PMID: 11029005]
Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14(8): 959-69.
[] [PMID: 10853977]
Lacabaratz-Porret C, Urrutia A, Doisne J-M, et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003; 187(5): 748-57.
[] [PMID: 12599048]
Orrell C, Kaplan R, Wood R, Bekker LG. Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy. Aids Res Treat 2011; 2011: 469127.
[] [PMID: 21716724]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy